Nick Boyle, PhD, on Advantages of In Vivo CAR Therapies
The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
“We were treating patients with hemophilia, with intravenous (IV) delivered vector, and we observed immune cell transduction after IV delivery. And with the advent of ex vivo CAR-T therapies... We realized we could actually administer these CAR therapies directly in vivo; generate them directly in vivo. And if we could achieve that, then we could address many of the patient unmet needs that exist today.”
While autologous chimeric antigen receptor T-cell (CAR-T) therapies have shown some great initial success, patient access has remained limited due to the ex vivo manufacturing processes many of these therapies use, and most are only available in handful of centers of excellence.
CGTLive spoke with Nick Boyle, PhD, chief executive officer, Abintus Bio, at the
Boyle also talked about methods for bringing cell therapies to underserved communities of patients. He discussed the importance of engaging clinical trial sites beyond the centers of excellence and how community hospitals participating in phase 1 programs can increase awareness and enrollment.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Trends in RNA Therapeutic Research
September 8th 2025
- The Therapeutic Potential of Circular RNA
September 7th 2025